Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
US10273474B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2013 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Mar 14, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.